PET/CT Limitations and Pitfalls in Urogenital Cancers.

Abstract

Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignancies. Its diagnostic value in urogenital malignancies is less well-known, not at least because of the variable FDG avidity of these tumor entities, the sites of these tumors, and technical challenges associated with sequential imaging of CT and PET. PET/CT interpretation thus can be especially challenging and is associated with many pitfalls, which can lead to both false-positive and false-negative diagnoses as well as incorrect assessment of metabolic change following therapy. Currently, FDG PET/CT is not the standard of care for the initial diagnosis or staging of early-stage or low-risk urogenital cancers; however, it can help evaluate distant metastatic disease, response to therapy, and disease recurrence in high-risk patients. Knowledge of imaging features of tumor metabolic avidity and pitfalls is essential for accurate interpretation.

• Authors: Anil Vasireddi, Nghi C Nguyen
• Journal: Seminars in nuclear medicine (Semin Nucl Med) Vol. 51 Issue 6 Pg. 611-620 (11 2021) ISSN: 1558-4623 [Electronic] United States
• PMID: 34243903 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Fluorodeoxyglucose F18

Topics

• Fluorodeoxyglucose F18
• Humans
• Neoplasm Recurrence, Local
• Positron Emission Tomography Computed Tomography
• Positron-Emission Tomography
• Urogenital Neoplasms (diagnostic imaging)